|
Aug 5
|
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 5
|
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update
|
|
Aug 1
|
Canaccord Genuity Maintained a Buy Rating on Rhythm Pharmaceuticals (RYTM)
|
|
Jul 30
|
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
|
Jul 29
|
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline
|
|
Jul 22
|
Rhythm Pharmaceuticals to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
|
|
Jul 21
|
Should You Invest in This Under-the-Radar Weight Loss Stock?
|
|
Jul 12
|
Rhythm Pharmaceuticals Presents Data on MC4R Agonists Setmelanotide and Bivamelagon at ENDO 2025
|
|
Jul 12
|
Investing.com’s stocks of the week
|
|
Jul 10
|
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
|
|
Jul 10
|
Rhythm Pharmaceuticals (RYTM) Stock Jumps 36.6%: Will It Continue to Soar?
|
|
Jul 10
|
Rhythm’s stock climbs on encouraging Phase II obesity drug data
|
|
Jul 10
|
Rhythm Pharmaceuticals, Inc. Announces Pricing of Upsized Public Offering of Common Stock
|
|
Jul 9
|
Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity
|
|
Jul 9
|
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
|
|
Jul 9
|
US Equity Markets Higher, Nasdaq Reaches New Record High Following Nvidia Milestone
|
|
Jul 9
|
Sector Update: Health Care Stocks Softer Wednesday Afternoon
|
|
Jul 9
|
Update: Rhythm Pharmaceuticals Shares Surge After Bivamelagon Reduces BMI in Hypothalamic Obesity Trial
|
|
Jul 9
|
Rhythm Pharmaceuticals Says Bivamelagon Cut BMI in Phase 2 Hypothalamic Obesity Study
|
|
Jul 9
|
Rhythm Pharmaceuticals Announces Oral MC4R Agonist Bivamelagon Achieved Statistically Significant, Clinically Meaningful BMI Reductions in Placebo-controlled Phase 2 Trial in Acquired Hypothalamic Obesity
|